ARCH Venture
Venture capitalActively deployingChicago · 9 people tracked
Find your way into ARCH Venture
Fund manager profile
ARCH Venture is a venture fund manager based in Chicago. SEC filings show 2 venture funds on record, most recently ARCH Venture Fund XIV, L.P. ($3B offering) filed August 2026.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 9 people
from public directoriesWhat they invest in
from 5 of 5 portfolio companiesBiotech ×4Medical Devices ×2AI & Machine Learning ×1Cloud Computing ×1Cybersecurity ×1Developer Tools ×1Digital Health ×1Healthtech ×1
HQs:United States×4
Investments · 5 tracked
founders shown can be your intro pathDenali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)Steve E. Krognes(Director)
Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalForesite CapitalFlagship VenturesGV (Google Ventures)
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalNextech InvestOUP (Osage University Partners)
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Co-investorsAisling CapitalARCH Venture PartnersEcoR1 CapitalPolaris Partners
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)
Co-investorsSamsara BioCapitalARCH Venture PartnersEcoR1 CapitalPolaris Partners
Maze is a security company, founded in 2024, that uses AI to help defenders identify and address vulnerabilities in code and cloud environments.
AI & Machine LearningCloud ComputingCybersecurityDeveloper Tools
Co-investorsTapestry VCTheory Ventures
Exits · 4
4 IPOsDenali TherapeuticsNASDAQ: DNLIKura OncologyNASDAQ: KURAScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRK
Portfolio news
latest coverage across their companiesMaze · defenseworld.net · Aug 26, 2026
Denali Therapeutics · finance.yahoo.com · Jul 15, 2026
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Denali Therapeutics | 12.6% | $18.00 | Dec 2017 | $199.2M |
| Scholar Rock | 10.8% | $14.00 | May 2018 | $36.9M |
| Scholar Rock Holding Corp, Inc. | 10.8% | $14.00 | May 2018 | $36.9M |
| Kura Oncology | 9.3% | $8.00 | Nov 2015 | $10.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has ARCH Venture made?
- ARCH Venture has 5 tracked investments, 4 of which have exited, including 1 dated in the last 24 months.
- Where is ARCH Venture located?
- ARCH Venture is headquartered in Chicago, US.
Media · Podcasts & interviews
featuring the teamARCH Venture's Kristina Burow on Investing in "Truly Transformative" Science
Falk Marques Group: Interviews With Women in Private Equity · Kristina Burow